How Five Medtech Trends Are Reshaping Global Commerce and Competitive Strategy

Executive Summary

The medical technology (medtech) sector is at a strategic inflection point. As 2026 approaches, five trends are converging to redefine how medical devices are priced, produced, distributed, and integrated into clinical practice. From Mainland China's expanding volume-based procurement (VBP) program to the accelerating shift of procedures to outpatient settings, from supply chain pressures that are rewriting manufacturing playbooks to the ripple effects of GLP-1 therapies and the emergence of platform-based competition, medtech companies must recalibrate their strategies for a more complex and demanding global marketplace.

These trends are not isolated; they are interrelated forces that demand a holistic response from corporate leaders. The commercial implications span portfolio strategy, operational footprint, pricing models, customer engagement, and long-term investment. Organizations that view these shifts as operational challenges rather than strategic opportunities will likely cede ground to more agile competitors.

This article synthesizes the latest market intelligence from Clarivate's Medtech Trends to Watch 2026 report and provides an executive-level analysis of why these trends matter, how they are shaping global commerce, and what strategic responses are required.

Introduction

For decades, medtech companies operated in a relatively predictable environment: innovation drove premium pricing, regulatory approvals created barriers to entry, and geographic expansion followed established patterns. That era is ending. A combination of policy changes, technological disruption, and shifting care delivery models is compressing margins, altering demand, and creating new competitive ecosystems.

The global medtech market remains substantial—valued at hundreds of billions of dollars—but growth is increasingly uneven. Some regions and therapeutic categories are expanding rapidly, while others face price compression and volume stagnation. The ability to anticipate and adapt to these structural changes will separate market leaders from laggards.

This article identifies five critical trends that will shape the medtech landscape in 2026 and beyond. For each trend, we examine the underlying dynamics, commercial significance, and strategic implications for businesses operating across borders.

Market Context

The global medical device industry has traditionally been characterized by high R&D intensity, rigorous regulatory oversight, and strong clinical evidence requirements. However, recent developments are altering the commercial environment in fundamental ways:

• Cost containment pressures globally have intensified, with payers and governments seeking to reduce healthcare expenditure.
• Technology convergence is blurring the lines between medical devices, software, data analytics, and artificial intelligence.
• Care setting migration is shifting procedures from hospitals to outpatient facilities, changing purchasing dynamics and product requirements.
• Geopolitical fragmentation is disrupting global supply chains and trade flows.

These trends are not cyclical but reflect deep structural changes in how healthcare is delivered and paid for. Medtech companies must therefore look beyond sales forecasts and examine the underlying architecture of their markets.

Main Analysis

1. Mainland China's VBP Expansion: Redefining Global Market Economics

Mainland China's national volume-based procurement (VBP) program has evolved from a tool to expand patient access into a powerful market-structuring mechanism. The latest rounds introduce more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers. For multinational medtech companies, VBP is no longer a localized policy issue; it is reshaping expectations about price, volume, and competitive positioning in markets well beyond China's borders.

The strategic implications are significant. As VBP drives down prices for commoditized devices, multinationals must reassess their portfolio strategies. High-end, differentiated products may still command premium prices, but even these face pressure as the program expands into new categories. The policy also accelerates domestic innovation, as Chinese competitors gain market share and use their scale to invest in R&D. Multinationals must decide whether to compete head-on, partner with local firms, or exit certain product lines.

Why it matters globally: VBP's influence extends through global pricing benchmarks. Procurement officials in other countries often reference China's pricing levels, creating a downward pricing spiral across emerging markets. Companies that fail to adapt their cost structures and value propositions will find themselves squeezed in both China and other price-sensitive markets.

2. Outpatient and ASC Settings: The Center of Procedure Strategy

The migration of procedures from hospital inpatient settings to outpatient ambulatory surgical centers (ASCs) and other low-acuity facilities is accelerating. The U.S. Centers for Medicare & Medicaid Services (CMS) 2026 Hospital Outpatient Prospective Payment System (OPPS) and ASC Payment System Final Rule expands the ASC Covered Procedure List and phases out the inpatient-only list, enabling higher-acuity procedures like cardiac ablation to be performed in lower-cost settings.

For medtech companies, this migration has profound commercial consequences. Product design must accommodate the workflows and space constraints of ASCs. Economic value propositions must emphasize not just clinical outcomes but also efficiency, cost savings, and staff utilization. Sales and service models must reach a fragmented base of smaller facilities rather than a consolidated hospital procurement function.

Orthopedics and general surgery have already seen significant ASC growth. The expansion into cardiovascular and other specialties opens new opportunities for companies prepared to adapt. Those that continue to focus solely on hospitals risk losing access to a growing segment of the market.

Why it matters: The shift to outpatient settings is not a US-only phenomenon. Similar trends are evident in other developed markets, driven by cost pressures and technological advances that enable minimally invasive procedures. Companies must develop comprehensive site-of-care strategies that optimize their offerings for each setting.

3. Supply Chain and Trade Pressures: Reshaping Manufacturing Strategy

Global trade tensions, tariff exposure, and material cost volatility are challenging long-held assumptions about where and how medical devices are manufactured. Supply chain resilience has become a strategic imperative, prompting companies to diversify sourcing, reevaluate business strategies, and move toward more flexible multi-region manufacturing footprints.

Large manufacturers are leveraging scale and vertical integration to buffer against global volatility. They are investing in automation, digital twins, and advanced logistics to reduce dependence on single sources. Smaller companies, by contrast, face higher barriers and may need to form partnerships or rely on contract manufacturers with diversified operations.

Trade policy is a critical wildcard. Tariffs on medical devices and components can alter cost structures overnight. Companies must model multiple scenarios and build flexibility into their supply chains. Nearshoring and friendshoring trends are gaining momentum, with production moving closer to key markets or to geopolitical allies.

Why it matters: Competitive advantage in medtech will increasingly depend on supply chain architecture, not just product performance. Companies that can maintain continuity of supply while managing costs will be better positioned to weather global volatility and gain share.

4. GLP-1 Therapies: Shifting Patient Behavior and Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management and diabetes care is reshaping patient behavior and clinical pathways. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s have expanded the addressable population and altered referral patterns.

The impact on medtech is uneven. Bariatric device volume is under pressure, especially for procedures with less severe obesity indications. However, downstream effects are emerging across adjacent categories: sleep apnea management, cardiovascular monitoring, and diabetes care devices are all influenced by changing patient populations and treatment algorithms.

The long-term implications extend beyond direct competition with surgery. GLP-1s are changing how physicians and patients perceive medical intervention. Preventative and pharmacologic approaches may reduce demand for certain devices while increasing demand for monitoring and digital health tools. Medtech companies must monitor these shifts closely and adapt their product pipelines accordingly.

Why it matters: The GLP-1 effect illustrates the growing interconnectedness of pharmaceutical and device markets. Companies that view their products in isolation risk being blindsided by therapeutic substitution. Conversely, those that embrace complementary strategies can capture new value.

5. Enabling Technologies: The Shift to Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are becoming integral to medtech offerings. These enabling technologies allow companies to move beyond standalone devices to integrated platforms that support the entire procedural care pathway—from planning and execution to postoperative follow-up.

Platform-based competition is particularly evident in surgical robotics. Companies are investing heavily in ecosystems that include instruments, software, and data analytics. Emerging open-platform systems are challenging closed, proprietary architectures, potentially democratizing access and accelerating innovation.

The strategic implications are vast. Platform ecosystems create stickier customer relationships and generate valuable data that can drive continuous improvement and new service models. They also require different capabilities, including software development, AI/ML expertise, and systems integration. Medtech companies must decide whether to build, buy, or partner to compete in this new landscape.

Why it matters: Platform-based competition redefines industry boundaries and value chains. Companies that successfully build or-align with platforms can create enduring competitive advantage, while those that focus only on individual products may face commoditization.

Business Impact

Across all five trends, the business impact is profound:

• Corporate Strategy: Portfolio decisions must reflect price compression, site-of-care dynamics, and technological shifts. Companies need to prioritize investment in growth areas while divesting or repositioning mature products.
• Commercial Competitiveness: Sales models, pricing strategies, and customer engagement must adapt to new purchasing environments. ASCs and outpatient centers require different approaches than hospital systems.
• Operations: Supply chain resilience is not just a cost issue; it is a competitive differentiator. Companies must invest in flexible manufacturing and sourcing.
• International Trade: Tariffs, export controls, and local-content requirements are altering trade flows. Companies need to align manufacturing and market access strategies.
• Innovation: The rise of enabling technologies requires new R&D capabilities and partnerships. Software and data are as important as hardware.
• Investment and Financial Performance: These trends affect revenue growth, margin stability, and capital allocation. Investors are increasingly scrutinizing companies' strategic responses.

Executive Insights

For chief executives and business leaders, several strategic priorities emerge:

• Adopt a site-of-care lens: Develop product designs, economic models, and commercial strategies tailored to the full range of care settings, from hospitals to home.
• Build supply chain agility: Diversify suppliers, invest in risk analytics, and create flexible manufacturing networks that can respond to geopolitical shifts.
• Monitor therapeutic substitution: Integrate pharma and device intelligence to anticipate demand shifts like those caused by GLP-1s.
• Invest in platform capabilities: Recognize that data, software, and AI are essential to future competitiveness. Build or partner to create integrated solutions.
• Rethink China strategy: Given VBP's trajectory, consider segmented approaches that balance market access, margin preservation, and intellectual property protection.
• Enhance cost competitiveness: To survive in a price-sensitive global environment, companies must reengineer product costs and operational efficiencies.
• Embrace open innovation: Partner with startups, tech firms, and academic institutions to accelerate innovation in enabling technologies and digital workflows.

Future Outlook

The next three to ten years will be transformative for the medtech industry. We expect:

• Continued globalization of value-based procurement: China's VBP model may be emulated by other large emerging markets, accelerating global price convergence.
• Further care migration: Advances in minimally invasive technology and remote monitoring will push more procedures into outpatient and home settings, potentially blurring the lines between medical devices and consumer health.
• Supply chain regionalization: Trade tensions and risk management will drive deeper regional manufacturing clusters, with Asia-Pacific, North America, and Europe each serving their respective markets.
• GLP-1 ripple effects: As these therapies become more affordable and accessible, their impact will extend across multiple therapeutic areas, from cardiovascular disease to chronic kidney disease, reshaping broader medtech demand.
• Platform ecosystems as market standards: Within 10 years, many devices will be designed as components of larger digital platforms. Interoperability and data sharing will be essential; proprietary lock-in may become less accepted.

Artificial intelligence and generative AI will play a pivotal role in enabling these trends. From supply chain optimization to clinical decision support to regulatory compliance, AI will be embedded throughout the medtech value chain. Companies that harness AI effectively will likely gain significant competitive advantages.

The medtech industry is thus on the cusp of a new era. The strategies that succeeded in the past—based on regulatory moats, premium pricing, and relationship-based selling—will need to be supplemented with new capabilities in digital technology, supply chain management, and ecosystem orchestration.

Conclusion

The five medtech trends highlighted here—China’s VBP expansion, outpatient migration, supply chain pressures, GLP-1’s clinical impact, and platform-based competition—are not separate phenomena. They reflect an industry moving toward greater value orientation, technological integration, and operational agility. Executives who recognize the interconnectedness of these trends and respond with coherent strategies will be better positioned for sustained success.

As the global commerce landscape evolves, medtech companies must remain alert to new policy developments, emerging technologies, and shifting customer expectations. The ability to transform business models—rather than merely adjust tactics—will define the industry leaders of 2030.

Key Takeaways

• Mainland China’s VBP expansion is setting global pricing benchmarks and accelerating domestic innovation, requiring multinationals to rethink portfolio and market strategies.
• The shift to outpatient and ASC settings demands new product designs, commercial models, and value propositions that align with lower-cost care delivery.
• Supply chain resilience is now a strategic imperative, with tariffs and geopolitical risks forcing companies to diversify manufacturing and sourcing.
• GLP-1 therapies are changing patient behavior and care pathways, with ripple effects across bariatric, cardiac, and monitoring device markets.
• Platform-based competition, enabled by robotics, imaging, and digital workflows, is redefining how medtech companies create and capture value.

Sources

• Clarivate. "5 medtech trends to watch in 2026." Accessed April 2026. https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026
• Clarivate. "Medtech Trends to Watch 2026" e-book. https://clarivate.com/life-sciences-healthcare/lp/medtech-trends-to-watch-in-2026/